Effect of high mobility group box 1 on Toll-like receptor 9 in B cells in myeloperoxidase-ANCA-associated vasculitis

References

• Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.
   PubMed Web of Science ®Google Scholar
• Shi L. Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes. Rheumatol Int. 2017;37(11):1779–1788.
   PubMed Web of Science ®Google Scholar
• Li ZY, Chang DY, Zhao MH, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 439 cases in a single Chinese center. Arthritis Rheumatol. 2014;66(7):1920–1926.
   PubMed Web of Science ®Google Scholar
• Goodwin GH, Johns EW. The isolation and purification of the high mobility group (HMG) nonhistone chromosomal proteins. Methods Cell Biol. 1977;16:257–267.
   PubMedGoogle Scholar
• Muller S, Scaffidi P, Degryse B, et al. New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J. 2001;20(16):4337–4340.
   PubMed Web of Science ®Google Scholar
• Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 2012;8(4):195–202.
   PubMed Web of Science ®Google Scholar
• Deng H, Wang C, Chang DY, et al. High mobility group box-1 contributes to anti-myeloperoxidase antibody-induced glomerular endothelial cell injury through a moesin-dependent route. Arthritis Res Ther. 2017;19(1):125.
   PubMedGoogle Scholar
• Wang C, Wang H, Chang DY, et al. High mobility group box 1 contributes to anti-neutrophil cytoplasmic antibody-induced neutrophils activation through receptor for advanced glycation end products (RAGE) and Toll-like receptor 4. Arthritis Res Ther. 2015;17(1):64.
   PubMedGoogle Scholar
• Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2004;17(1):1–14.
   Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408(6813):740–745.
   PubMed Web of Science ®Google Scholar
• Krug A, Luker GD, Barchet W, et al. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood. 2004;103(4):1433–1437.
   PubMed Web of Science ®Google Scholar
• Lund J, Sato A, Akira S, et al. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med. 2003;198(3):513–520.
   PubMed Web of Science ®Google Scholar
• Ehlers M, Fukuyama H, McGaha TL, et al. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med. 2006;203(3):553–561.
   PubMed Web of Science ®Google Scholar
• Hirotani M, Niino M, Fukazawa T, et al. Decreased IL-10 production mediated by Toll-like receptor 9 in B cells in multiple sclerosis. J Neuroimmunol. 2010;221(1–2):95–100.
   PubMed Web of Science ®Google Scholar
• Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002;416(6881):603–607.
   PubMed Web of Science ®Google Scholar
• Tadema H, Abdulahad WH, Lepse N, et al. Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission. Rheumatology. 2011;50(4):689–696.
   PubMed Web of Science ®Google Scholar
• Wen Z, Xu L, Chen X, et al. Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/microRNA-155 pathway. J Immunol. 2013;190(11):5411–5422.
   PubMed Web of Science ®Google Scholar
• Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87(11):671–678.
   PubMed Web of Science ®Google Scholar
• Lepse N, Land J, Rutgers A, et al. Toll-like receptor 9 activation enhances B cell activating factor and interleukin-21 induced anti-proteinase 3 autoantibody production in vitro. Rheumatology (Oxford). 2016;55(1):162–172.
   PubMed Web of Science ®Google Scholar
• Boldt A, Borte S, Fricke S, et al. Eight-color immunophenotyping of T-, B-, and NK-cell subpopulations for characterization of chronic immunodeficiencies. Cytometry B Clin Cytom. 2014;86(3):191–206.
   PubMed Web of Science ®Google Scholar
• Liu Y, Gong Y, Qu C, et al. CD32b expression is down-regulated on double-negative memory B cells in patients with Hashimoto's thyroiditis. Mol Cell Endocrinol. 2017;440:1–7.
   PubMed Web of Science ®Google Scholar
• De S, Zhang B, Shih T, et al. B cell-intrinsic role for IRF5 in TLR9/BCR-induced human B cell activation. Front Immunol. 2017;8:1938.
   PubMed Web of Science ®Google Scholar
• Masum MA, Ichii O, Hosny Ali Elewa Y, et al. Overexpression of toll-like receptor 9 correlates with podocyte injury in a murine model of autoimmune membranoproliferative glomerulonephritis. Autoimmunity. 2018;51(8):386–398.
   PubMed Web of Science ®Google Scholar
• Papadimitraki ED, Choulaki C, Koutala E, et al. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum. 2006;54(11):3601–3611.
   PubMedGoogle Scholar
• Vos Q, Lees A, Wu ZQ, et al. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev. 2000;176:154–170.
   PubMed Web of Science ®Google Scholar
• Jiang W, Lederman MM, Harding CV, et al. TLR9 stimulation drives naive B cells to proliferate and to attain enhanced antigen presenting function. Eur J Immunol. 2007;37(8):2205–2213.
   PubMed Web of Science ®Google Scholar
• Gestermann N, Di Domizio J, Lande R, et al. Netting neutrophils activate autoreactive B cells in lupus. J Immunol. 2018;200(10):3364–3371.
   PubMed Web of Science ®Google Scholar
• Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood. 2003;101(11):4500–4504.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Suzuki Y, Narita I, et al. Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol. 2008;19(12):2384–2395.
   PubMed Web of Science ®Google Scholar
• Ma TT, Wang H, Wang C, et al. Urinary levels of high mobility group box-1 are associated with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis. PLoS One. 2015;10(4):e0123586.
   PubMed Web of Science ®Google Scholar
• Wang C, Gou S-J, Chang D-Y, et al. Association of circulating level of high mobility group box 1 with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Care Res. 2013;65(11):1828–1834.
   Web of Science ®Google Scholar
• Ma YH, Ma TT, Wang C, et al. High-mobility group box 1 potentiates antineutrophil cytoplasmic antibody-inducing neutrophil extracellular traps formation. Arthritis Res Ther. 2016;18(1):2.
   PubMedGoogle Scholar
• Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007;8(5):487–496.
   PubMed Web of Science ®Google Scholar
• Avalos AM, Kiefer K, Tian J, et al. RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes. Autoimmunity. 2010;43(1):103–110.
   PubMed Web of Science ®Google Scholar
• Jia L, Clear A, Liu FT, et al. Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood. 2014;123(11):1709–1719.
   PubMed Web of Science ®Google Scholar
• Li JH, Zhao B, Zhu XH, et al. Blockade of extracellular HMGB1 suppresses xenoreactive B cell responses and delays acute vascular xenogeneic rejection. Am J Transplant. 2015;15(8):2062–2074.
   PubMed Web of Science ®Google Scholar
• Agier J, Brzezińska-Błaszczyk E, Żelechowska P, et al. Cathelicidin LL-37 affects surface and intracellular Toll-like receptor expression in tissue mast cells. J Immunol Res. 2018;2018:1.
   Google Scholar
• Zhang Y, Shi W, Tang S, et al. The influence of cathelicidin LL37 in human anti-neutrophils cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res Ther. 2013;15(5):R161.
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–232.
   PubMed Web of Science ®Google Scholar
• Voswinkel J, Assmann G, Held G, et al. Single cell analysis of B lymphocytes from Wegener's granulomatosis: B cell receptors display affinity maturation within the granulomatous lesions. Clin Exp Immunol. 2008;154(3):339–345.
   PubMed Web of Science ®Google Scholar
• Hoffman W, Lakkis FG, Chalasani G. B cells, antibodies, and more. Clin J Am Soc Nephrol. 2016;11(1):137–154.
   PubMed Web of Science ®Google Scholar
• Neel A, Bucchia M, Neel M, et al. Dampening of CD8+ T cell response by B cell depletion therapy in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2019;71(4):641–650.
   PubMed Web of Science ®Google Scholar